KEGG   DRUG: ReslizumabHelp
Entry
D08985                      Drug                                   

Name
Reslizumab (USAN);
Cinqaero (TN)
Product
Remark
ATC code: 
Activity
Antiasthmatic, IL-5 antagonist
  Disease
Severe asthma (eosinophilic phenotype)
Comment
Monoclonal antibody
Target
IL5 [HSA:3567] [KO:K05428]
  Pathway
Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
    R03DX Other systemic drugs for obstructive airway diseases
     R03DX08 Reslizumab
      D08985  Reslizumab (USAN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  Class I cytokines
   IL-5
    Reslizumab
     D08985  Reslizumab (USAN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D08985
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08985
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D08985
BRITE hierarchy
Other DBs
CAS: 
241473-69-8
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system